Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

about

Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.

P2860

Q38657864-1866181F-4319-4180-9BA8-73CD2F49F904

P2860

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

Item

http://www.wikidata.org/entity/Q26771947

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@ast

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@en

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@nl

type

Item

label

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@ast

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@en

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@nl

prefLabel

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@ast

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@en

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@nl

P1476

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

@en

P2093

Ellen M Hanisch

http://www.w3.org/2001/XMLSchema#string

Jasmine R Martin

http://www.w3.org/2001/XMLSchema#string

Nancy L Beegle

http://www.w3.org/2001/XMLSchema#string

Yanyan Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Cancer statistics, 2015

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.

Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy

Performing subcutaneous injections: a literature review.

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.

P304

308-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JADPRO.2015.6.4.2

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26705492

http://www.w3.org/2001/XMLSchema#string

P932

4677804

http://www.w3.org/2001/XMLSchema#string

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

about

P2860

P2860

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932